Obermatt
See Similar Stocks →

Spyre Therapeutics

NSQ:SYRE · US00773J2024
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings100
Price/Book7
Dividend Yield—
Revenue Growth1
Profit Growth25
Capital Growth57
TSR 52w94
Leverage18
Liquidity—
Refinancing61
Combined—
Analyst Opinions100
Pro Holdings95
Opinion Changes50
Market Pulse49

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2013
Employees93
Websitespyre.com
ISINUS00773J2024
Last UpdateApr 2, 2026
Index & Theme
ImmunologyChronic DiseasesRheumatologyGastroenterologyInflammationBiotechnologyTherapeutics

Description

Spyre Therapeutics, Inc. (Spyre) operates as a clinical-stage biotechnology company. The company is pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (‘IBD’), and rheumatic di…

Similar Stocks

The companies this stock is ranked against.

Compare Spyre Therapeutics with its peers
Shattuck Labs
NSQ:STTK
50
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pyxis Oncology
NSQ:PYXS
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xbiotech
NSQ:XBIT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →